Add to ORKGFurther reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 year
Context: Denosumab discontinuation is characterized by an increase in bone turnover overriding pretr...
Denosumab is an approved therapy for postmenopausal women with osteoporosis at high or increased ris...
Dual-energy X-ray absorptiometric bone mineral density (DXA BMD) is a strong predictor of fracture r...
Summary: Limited data exist on the efficacy of long-term therapies for osteoporosis. In osteoporotic...
Limited data exist on the efficacy of long-term therapies for osteoporosis. In osteoporotic postmeno...
Limited data exist on the efficacy of long-term therapies for osteoporosis. In osteoporotic postmen...
CONTEXT: Evidence for further nonvertebral fracture (NVF) reductions with long-term antiresorptive t...
sfcc-cpmc.net. *Investigators for the Fracture Reduction Evaluation of Denosumab in Osteoporo-sis Ev...
Summary In a phase 2 study, continued denosumab treat-ment for up to 8 years was associated with con...
Osteoporosis is a chronic disease and requires long-term treatment with pharmacologic therapy to ens...
UNLABELLED The FREEDOM study and its Extension provide long-term information about the effects of...
Summary: This post-hoc analysis queried whether women experiencing fracture on denosumab indicates i...
The FREEDOM study and its Extension provide long-term information about the effects of denosumab for...
Context: Denosumab discontinuation is characterized by an increase in bone turnover overriding pretr...
Denosumab is a novel medication used to prevent fractures in osteoporosis. It has been shown to be e...
Context: Denosumab discontinuation is characterized by an increase in bone turnover overriding pretr...
Denosumab is an approved therapy for postmenopausal women with osteoporosis at high or increased ris...
Dual-energy X-ray absorptiometric bone mineral density (DXA BMD) is a strong predictor of fracture r...
Summary: Limited data exist on the efficacy of long-term therapies for osteoporosis. In osteoporotic...
Limited data exist on the efficacy of long-term therapies for osteoporosis. In osteoporotic postmeno...
Limited data exist on the efficacy of long-term therapies for osteoporosis. In osteoporotic postmen...
CONTEXT: Evidence for further nonvertebral fracture (NVF) reductions with long-term antiresorptive t...
sfcc-cpmc.net. *Investigators for the Fracture Reduction Evaluation of Denosumab in Osteoporo-sis Ev...
Summary In a phase 2 study, continued denosumab treat-ment for up to 8 years was associated with con...
Osteoporosis is a chronic disease and requires long-term treatment with pharmacologic therapy to ens...
UNLABELLED The FREEDOM study and its Extension provide long-term information about the effects of...
Summary: This post-hoc analysis queried whether women experiencing fracture on denosumab indicates i...
The FREEDOM study and its Extension provide long-term information about the effects of denosumab for...
Context: Denosumab discontinuation is characterized by an increase in bone turnover overriding pretr...
Denosumab is a novel medication used to prevent fractures in osteoporosis. It has been shown to be e...
Context: Denosumab discontinuation is characterized by an increase in bone turnover overriding pretr...
Denosumab is an approved therapy for postmenopausal women with osteoporosis at high or increased ris...
Dual-energy X-ray absorptiometric bone mineral density (DXA BMD) is a strong predictor of fracture r...